Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

urothelial carcinoma

  • You have access
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
    TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI and TAKASHI KOBAYASHI
    Anticancer Research May 2023, 43 (5) 2119-2126; DOI: https://doi.org/10.21873/anticanres.16373
  • Open Access
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder
    JETON LUZHA, NORBERT NASS, PIOTR CZAPIEWSKI, NICOLAS SCHROEDER, THOMAS KALINSKI, MARTIN SCHOSTAK, CHRISTOPH SCHATZ, BURKHARD JANDRIG and JOHANNES HAYBAECK
    Anticancer Research April 2023, 43 (4) 1437-1448; DOI: https://doi.org/10.21873/anticanres.16292
  • You have access
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells
    SAN-YUAN CHEN, CHUN-NUN CHAO, HSIN-YI HUANG, PEI-WEN ZHAO and CHIUNG-YAO FANG
    Anticancer Research March 2023, 43 (3) 1175-1184; DOI: https://doi.org/10.21873/anticanres.16263
  • You have access
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
    JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG
    Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
  • You have access
    Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
    IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO
    Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
  • You have access
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
    SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO
    Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851
  • You have access
    Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
    IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO
    Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638
  • You have access
    Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma
    RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, KEITA IZUMI, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, TOSHIHIKO IIZUKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA
    Anticancer Research February 2022, 42 (2) 1131-1136; DOI: https://doi.org/10.21873/anticanres.15576
  • You have access
    Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy
    AKINORI MINATO, HIROTSUGU NOGUCHI, RIEKO KIMURO, HARADA MIRII, NAGATA YUJIRO, YOSHITAKA HASEGAWA, IKKO TOMISAKI, KENICHI HARADA and NAOHIRO FUJIMOTO
    Anticancer Research January 2022, 42 (1) 263-269; DOI: https://doi.org/10.21873/anticanres.15481
  • You have access
    Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers
    MACIEJ KACZOROWSKI, JOANNA MATYSIAK, PAWEL KIELB, BARTOSZ MALKIEWICZ and AGNIESZKA HALON
    Anticancer Research January 2022, 42 (1) 493-500; DOI: https://doi.org/10.21873/anticanres.15507

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire